CK Life Sciences (HKG:0775) swung to an attributable loss of HK$126.6 million in 2024 from a profit of HK$17.3 million in 2023, according to a Tuesday filing with the Hong Kong bourse.
The biotechnology company swung to a loss per share of HK$0.0132 from earnings per share of HK$0.0018 in the previous year.
Revenue increased to HK$5.52 billion compared with HK$5.32 billion in the previous year.
Shares slid 3% during Wednesday's morning trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。